Accordingly, Choi et al. designed and evaluated EGFRvIII specific CAR-T cell secreting EGFR-specific BiTE antibody (BiTE-CAR-T Cell) against glioblastoma mouse model, which indicated the potential efficacy in eliminating the heterogeneous tumor cells without any significant toxicity [106]. This evidence concerns the gene EGFR and neoplasm.